Velox
SKIN THERAPEUTICS

Netherton Syndrome is a severe hereditary skin disease, with serious infection, inflammation, and desquamation symptoms for which there is currently no satisfactory treatment. We developed a peptide based therapeutic to treat patients in a systemic approach, drastically improving their quality of life.

Our clients

There are approximately 5'000 patients in Europe and US suffering from NS. Newborns are especially vulnerable to concomitant dehydration and infection that can be lethal.

How do we make money?

NS is classified as a rare disease with no current treatment, facilitating validation processes. Furthermore, our orphan drug will be first-in-class with premium pricing and further potential.

Our expertise

We are working in close collaboration with scientific and medical experts in the field, both at EPFL and at INSERM in Paris. Our peptide-based drug is already potent in an animal model and we are filing a patent.

"Breakthrough cure for severe hereditary skin disease"

Next steps

In the next 6 months we will further validate our *in vivo* data and initiate preliminary toxicology studies. We will file a patent before the end of the year and apply for further grants, such as Innogrant and Enable.

To continue the development we will hire another researcher to organise the preclinical studies. We are planning on outsourcing drug production, as well as toxicology studies.

We are especially looking for further coaching, and funding in the form of grants or business angels.

Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

Swiss Confederation

Innosuisse – Swiss Innovation Agency

Patrick Gonschorek
MSc

Marilena Schwaderlapp
MSc

François Rivest
MSc

Jordi Mollà Mas
BSc